GREENWICH, Conn.--(BUSINESS WIRE)--Jan. 5, 2006--Breakthrough Therapeutics, a privately owned biotechnology company, today announced the presentation of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R); Novartis). This two-year follow-up data was presented at the annual American Society of Hematology Meeting held in Atlanta, GA. VAX100 is a BCR-ABL peptide vaccine designed to reduce persistent disease in patients with CML whom have had stable disease during conventional therapy. Breakthrough Therapeutics has licensed peptides associated with the BCR-ABL breakpoint (including those used in VAX100) from Memorial Sloan Kettering Cancer Center (MSKCC).
